197 related articles for article (PubMed ID: 35441753)
1. IL-27 improves adoptive CD8
Ding M; Fei Y; Zhu J; Ma J; Zhu G; Zhen N; Zhu J; Mao S; Sun F; Wang F; Pan Q
Cancer Sci; 2022 Jul; 113(7):2258-2271. PubMed ID: 35441753
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
[TBL] [Abstract][Full Text] [Related]
3. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
5. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
7. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
8. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Hinrichs CS; Spolski R; Paulos CM; Gattinoni L; Kerstann KW; Palmer DC; Klebanoff CA; Rosenberg SA; Leonard WJ; Restifo NP
Blood; 2008 Jun; 111(11):5326-33. PubMed ID: 18276844
[TBL] [Abstract][Full Text] [Related]
9. Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.
Furusawa A; Reiser J; Sadashivaiah K; Simpson H; Banerjee A
J Immunother; 2018; 41(2):53-63. PubMed ID: 29271784
[TBL] [Abstract][Full Text] [Related]
10. Type 17 CD8+ T cells display enhanced antitumor immunity.
Hinrichs CS; Kaiser A; Paulos CM; Cassard L; Sanchez-Perez L; Heemskerk B; Wrzesinski C; Borman ZA; Muranski P; Restifo NP
Blood; 2009 Jul; 114(3):596-9. PubMed ID: 19471017
[TBL] [Abstract][Full Text] [Related]
11. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.
Lisiero DN; Soto H; Liau LM; Prins RM
J Immunol; 2011 May; 186(9):5068-77. PubMed ID: 21430221
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
14. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
15. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
16. IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.
Liu Z; Liu JQ; Talebian F; Wu LC; Li S; Bai XF
Eur J Immunol; 2013 Feb; 43(2):468-79. PubMed ID: 23225163
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
18. Loss of the orphan nuclear receptor NR2F6 enhances CD8
Jakic B; Olson WJ; Siegmund K; Klepsch V; Kimpel J; Labi V; Zehn D; Baier G; Hermann-Kleiter N
Cell Death Dis; 2021 Feb; 12(2):187. PubMed ID: 33589606
[TBL] [Abstract][Full Text] [Related]
19. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
